Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
For patients with diabetes who are also taking insulin or sulfonylureas, there is an increased risk of hypoglycaemia
Standard therapies face pressure where payers implement step therapy protocols favoring agents with cardiovascular outcomes data, while growth concentrates in molecules demonstrating superior weight reduction that justify premium pricing through obesity indication exclusivity
Needles with a sharp, well-designed bevel reduce pain and trauma during insertion
Who Is Eligible and Medical Necessity Standards GLP-1 medications are indicated for patients with type 2 diabetes, obesity (BMI 30 or 27 with weight-related comorbidities), or significant cardiovascular disease
US$ 21.58
US$ 27.63
US$ 24.41
US$ 27.48
US$ 29.02
US$ 25.02
US$ 24.81
US$ 27.58
US$ 24.84
